Latest filing published 11 Jun 2025 for Galectin Therapeutics INC.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -41.7%Entry US$7.46 · Close at T+365 US$4.35
- +125.5%Entry US$1.96 · Close at T+365 US$4.42
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
James C. Czirr: trading record in brief
All filings by James C. Czirr on record concern Galectin Therapeutics Inc. The record holds 98 filings, for trades running from 28 February 2006 to 6 June 2025.
On the open market, the record shows 2 purchases worth €23k and 36 sales worth €7.4M. Taken together, the sales exceed the purchases by €7.4M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 10 share grants and 21 option exercises.
The record was last updated on 11 June 2025 with a transaction in Galectin Therapeutics Inc. The clock since the last published purchase (18 November 2013) now reads 4,738 days. Filings reach the SEC (Form 4) feed a median of 5 days after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to James C. Czirr
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,000 sharesCommon StockSEC:0001641172-25-014756:1
- 1,000 shares@ US$6.000.1% of flowCommon StockSEC:0001641172-25-014756:2
- 31,250 shares@ US$0.890.3% of flowCommon StockSEC:0001641172-25-014756:3
- 46,875 shares@ US$2.391.4% of flowCommon StockSEC:0001641172-25-014756:4
- 25,000 shares@ US$4.721.4% of flowCommon StockSEC:0001641172-25-014756:5
- 30,000 shares@ US$2.861.0% of flowCommon StockSEC:0001641172-25-014756:6
- 40,000 shares@ US$2.111.0% of flowCommon StockSEC:0001641172-25-014756:7
- 70,000 shares@ US$2.111.8% of flowCommon StockSEC:0001641172-25-014756:8
- 40,000 shares@ US$1.981.0% of flowCommon StockSEC:0001641172-25-014756:9
- 40,000 shares@ US$1.110.5% of flowCommon StockSEC:0001641172-25-014756:10
- 10,000 sharesCommon StockSEC:0001641172-25-014756:0
- 3,677 shares@ US$3.060.1% of flowCommon StockSEC:0001493152-24-015877:1
- 21,323 shares@ US$3.06100.0% of flowCommon StockSEC:0001493152-24-015877:0
- 31,860 shares@ US$7.993.9% of flowCommon StockSEC:0001493152-18-009008:0
- 44,525 shares@ US$8.485.7% of flowCommon StockSEC:0001493152-18-009008:1
- 60,000 shares@ US$9.068.2% of flowCommon StockSEC:0001493152-18-009008:3
- 15,475 shares@ US$8.472.0% of flowCommon StockSEC:0001493152-18-009008:2
- 60,000 shares@ US$7.475.7% of flowCommon StockSEC:0001493152-18-008737:2
- 60,000 shares@ US$6.595.0% of flowCommon StockSEC:0001493152-18-008737:0
- 60,000 shares@ US$7.095.4% of flowCommon StockSEC:0001493152-18-008737:1
- 28,140 shares@ US$7.972.8% of flowCommon StockSEC:0001493152-18-008737:3
- 50,000 shares@ US$5.643.6% of flowCommon StockSEC:0001493152-18-008549:0
- 60,000 shares@ US$6.084.6% of flowCommon StockSEC:0001493152-18-008549:1
- 41,907 shares@ US$5.122.8% of flowCommon StockSEC:0001493152-18-008237:0
- 8,093 shares@ US$5.130.5% of flowCommon StockSEC:0001493152-18-008237:1
25 of 62 declarations
